BACKGROUND: Acquired resistance to second-line drugs (SLDs) is a problem in treating patients with drug-resistant tuberculosis worldwide. The objectives of this study were to identify risk factors for acquired resistance (AR) to injectable SLDs (INJ SLDs) and fluoroquinolones in the US National tuberculosis Surveillance System, 1993-2008. METHODS: We selected cases for which the initial and final drug susceptibility test (DST) results had been reported. We defined AR as resistance at the final DST but susceptibility to the same drug at the initial DST. We analyzed AR using 2-way frequency tables and multivariable logistic regression. RESULTS: The baseline prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis was 12.6% (1864/14 770) and 0.38% (56/14 770), respectively. Of 2274 individuals without initial resistance to INJ SLDs, 49 (2.2%) acquired resistance. Of 1141 initially susceptible to fluoroquinolones, 32 (2.8%) acquired resistance. The AR to INJ SLDs was associated with age group 25-44 years (adjusted odds ratio [aOR], 2.7; 95% confidence interval [CI], 1.2-6.3), positive HIV (human immunodeficiency virus) status (aOR, 2.5; 95% CI, 1.3-4.7), MDR at treatment initiation (aOR, 5.5; 95% CI, 2.9-10.5), and treatment with any SLD (aOR, 2.4; 95% CI,1.2-4.7). The AR to fluoroquinolones was associated with MDR tuberculosis at treatment initiation (aOR, 6.5; 95% CI, 2.9-14.6). CONCLUSIONS: Among patients with initial and final DST reported, the risk factors for AR to INJ SLDs included age, positive HIV status, MDR tuberculosis and initial treatment with any SLD, while the only predictor for AR to fluoroquinolones was MDR tuberculosis at treatment initiation. Providers should consider monitoring SLD DST for MDR tuberculosis patients in the indicated subgroups.
BACKGROUND: Acquired resistance to second-line drugs (SLDs) is a problem in treating patients with drug-resistant tuberculosis worldwide. The objectives of this study were to identify risk factors for acquired resistance (AR) to injectable SLDs (INJ SLDs) and fluoroquinolones in the US National tuberculosis Surveillance System, 1993-2008. METHODS: We selected cases for which the initial and final drug susceptibility test (DST) results had been reported. We defined AR as resistance at the final DST but susceptibility to the same drug at the initial DST. We analyzed AR using 2-way frequency tables and multivariable logistic regression. RESULTS: The baseline prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis was 12.6% (1864/14 770) and 0.38% (56/14 770), respectively. Of 2274 individuals without initial resistance to INJ SLDs, 49 (2.2%) acquired resistance. Of 1141 initially susceptible to fluoroquinolones, 32 (2.8%) acquired resistance. The AR to INJ SLDs was associated with age group 25-44 years (adjusted odds ratio [aOR], 2.7; 95% confidence interval [CI], 1.2-6.3), positive HIV (human immunodeficiency virus) status (aOR, 2.5; 95% CI, 1.3-4.7), MDR at treatment initiation (aOR, 5.5; 95% CI, 2.9-10.5), and treatment with any SLD (aOR, 2.4; 95% CI,1.2-4.7). The AR to fluoroquinolones was associated with MDR tuberculosis at treatment initiation (aOR, 6.5; 95% CI, 2.9-14.6). CONCLUSIONS: Among patients with initial and final DST reported, the risk factors for AR to INJ SLDs included age, positive HIV status, MDR tuberculosis and initial treatment with any SLD, while the only predictor for AR to fluoroquinolones was MDR tuberculosis at treatment initiation. Providers should consider monitoring SLD DST for MDR tuberculosispatients in the indicated subgroups.
Authors: Frank A Post; Paul A Willcox; Barun Mathema; Lafras M Steyn; Karen Shean; Srinivas V Ramaswamy; Edward A Graviss; Elena Shashkina; Barry N Kreiswirth; Gilla Kaplan Journal: J Infect Dis Date: 2004-05-28 Impact factor: 5.226
Authors: L L Han; A Sloutsky; R Canales; V Naroditskaya; S S Shin; K J Seung; R Timperi; M C Becerra Journal: Int J Tuberc Lung Dis Date: 2005-07 Impact factor: 2.373
Authors: Matteo Zignol; Wayne van Gemert; Dennis Falzon; Charalambos Sismanidis; Philippe Glaziou; Katherine Floyd; Mario Raviglione Journal: Bull World Health Organ Date: 2011-11-07 Impact factor: 9.408
Authors: Vaira Leimane; Vija Riekstina; Timothy H Holtz; Evija Zarovska; Vija Skripconoka; Lorna E Thorpe; Kayla F Laserson; Charles D Wells Journal: Lancet Date: 2005 Jan 22-28 Impact factor: 79.321
Authors: Smita Ghosh; Patrick K Moonan; Lauren Cowan; Juliana Grant; Steve Kammerer; Thomas R Navin Journal: Infect Genet Evol Date: 2011-10-25 Impact factor: 3.342
Authors: Edward D Chan; Valerie Laurel; Matthew J Strand; Julanie F Chan; Mai-Lan N Huynh; Marian Goble; Michael D Iseman Journal: Am J Respir Crit Care Med Date: 2004-01-23 Impact factor: 21.405
Authors: J Peter Cegielski; Ekaterina Kurbatova; Martie van der Walt; Jeannette Brand; Julia Ershova; Thelma Tupasi; Janice Campos Caoili; Tracy Dalton; Carmen Contreras; Martin Yagui; Jaime Bayona; Charlotte Kvasnovsky; Vaira Leimane; Liga Kuksa; Michael P Chen; Laura E Via; Soo Hee Hwang; Melanie Wolfgang; Grigory V Volchenkov; Tatiana Somova; Sarah E Smith; Somsak Akksilp; Wanpen Wattanaamornkiet; Hee Jin Kim; Chang-Ki Kim; Boris Y Kazennyy; Tatiana Khorosheva; Kai Kliiman; Piret Viiklepp; Ruwen Jou; Angela Song-En Huang; Irina A Vasilyeva; Olga V Demikhova; Joey Lancaster; Ronel Odendaal; Lois Diem; Therese C Perez; Tarcela Gler; Kathrine Tan; Cesar Bonilla; Oswaldo Jave; Luis Asencios; Gloria Yale; Carmen Suarez; Allison Taylor Walker; Inga Norvaisha; Girts Skenders; Ingrida Sture; Vija Riekstina; Andra Cirule; Erika Sigman; Sang-Nae Cho; Ying Cai; Seokyong Eum; Jongseok Lee; Seungkyu Park; Doosoo Jeon; Isdore C Shamputa; Beverly Metchock; Tatiana Kuznetsova; Rattanawadee Akksilp; Wanlaya Sitti; Jirapan Inyapong; Elena V Kiryanova; Irina Degtyareva; Evgenia S Nemtsova; Klavdia Levina; Manfred Danilovits; Tiina Kummik; Yung-Chao Lei; Wei-Lun Huang; Vladislav V Erokhin; Larisa N Chernousova; Sofia N Andreevskaya; Elena E Larionova; Tatyana G Smirnova Journal: Clin Infect Dis Date: 2015-10-27 Impact factor: 9.079
Authors: Russell R Kempker; Maia Kipiani; Veriko Mirtskhulava; Nestani Tukvadze; Matthew J Magee; Henry M Blumberg Journal: Emerg Infect Dis Date: 2015-06 Impact factor: 6.883
Authors: Sarah E Smith; Julia Ershova; Natalia Vlasova; Elena Nikishova; Irina Tarasova; Platon Eliseev; Andrey O Maryandyshev; Igor G Shemyakin; Ekaterina Kurbatova; J Peter Cegielski Journal: Emerg Infect Dis Date: 2015-06 Impact factor: 6.883
Authors: Miranda G Loutet; Jennifer A Davidson; Tim Brown; Martin Dedicoat; H Lucy Thomas; Maeve K Lalor Journal: Emerg Infect Dis Date: 2018-03 Impact factor: 6.883
Authors: Alireza Hadizadeh Tasbiti; Shamsi Yari; Mostafa Ghanei; Mohammad Ali Shokrgozar; Abolfazl Fateh; Ahmadreza Bahrmand Journal: Osong Public Health Res Perspect Date: 2017-04-30
Authors: Courtney M Yuen; Ekaterina V Kurbatova; Eleanor S Click; J Sean Cavanaugh; J Peter Cegielski Journal: PLoS One Date: 2013-12-23 Impact factor: 3.240
Authors: Giorgi Kuchukhidze; Davit Baliashvili; Natalia Adamashvili; Ana Kasradze; Russell R Kempker; Matthew J Magee Journal: Open Forum Infect Dis Date: 2021-03-15 Impact factor: 3.835